Improvement of insulin resistance and reduction of cardiovascular risk among obese patients with type 2 diabetes with the duodenojejunal bypass liner.

Autor: de Moura EG; Gastrointestinal Endoscopy Unit, Hospital das Clínicas, University of São Paulo School of Medicine, Av. Dr. Enéas de Carvalho Aguiar, 255-Cerqueira César, 05403-000, São Paulo, Brazil. eduardoghdemoura@gmail.com, Orso IR, Martins BC, Lopes GS, de Oliveira SL, Galvão-Neto Mdos P, Mancini MC, Santo MA, Sakai P, Ramos AC, Garrido-Júnior AB, Halpern A, Cecconello I
Jazyk: angličtina
Zdroj: Obesity surgery [Obes Surg] 2011 Jul; Vol. 21 (7), pp. 941-7.
DOI: 10.1007/s11695-011-0387-0
Abstrakt: Background: This study aims to evaluate the effectiveness of the duodenojejunal bypass liner (DJBL) in the improvement of insulin resistance and reduction of cardiovascular risk among morbidly obese patients with type 2 diabetes mellitus, using the triglyceride/high-density lipoprotein (HDL) cholesterol ratio, percentage of weight loss, and glycemic control.
Methods: We used the TG/HDL ratio with a cutoff value of 3.5 to identify patients with insulin resistance. The value of the initial ratio was compared with the ratio obtained 6 months after implantation to evaluate whether an improvement in insulin resistance occurred. We also evaluated the improvement of glycated hemoglobin levels and the weight loss resulted from the use of the device and correlated that with the improvement of the TG/HDL ratio.
Results: All patients implanted with the device presented a statistically significant reduction of the HbA1c levels, with most patients (70.3%) obtaining diabetes control with HbA1c levels lower than 7% at the end of the study. All patients also presented a significant weight reduction, with an average loss of 12.6% of their initial weight. We observed an important improvement in insulin resistance and metabolic syndrome, with a significant reduction of the TG/HDL ratio from 5.75 to 4.36 (p < 0.001) and 42.6% of the patients presenting a TG/HDL ratio lower than 3.5 at the end of the study.
Conclusions: The DJBL, when used for a period of 6 months, is effective in the control of diabetes, weight loss, improvement of insulin resistance, and decrease of cardiovascular risk among morbidly obese patients with type 2 diabetes mellitus.
Databáze: MEDLINE
Externí odkaz: